Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

CMS’s Updates to IRA Guidance Don’t Change Big-Picture Impact for Manufacturers

  • Post author:PacConAdmin
  • Post published:July 3, 2023
  • Post category:Drug Industry Daily

In the face of multiple lawsuits and 7,500 public comments, CMS adjusted some aspects of the Inflation Reduction Act’s drug price negotiation provisions, but the changes don’t lessen the law’s…

Continue ReadingCMS’s Updates to IRA Guidance Don’t Change Big-Picture Impact for Manufacturers

Amgen and Horizon File Counterclaim in FTC Antitrust Suit

  • Post author:PacConAdmin
  • Post published:July 3, 2023
  • Post category:Drug Industry Daily

The FTC’s lawsuit to block the merger of Amgen and Horizon violates the companies’ right to due process as, with the case relegated to an administrative law judge (ALJ) and…

Continue ReadingAmgen and Horizon File Counterclaim in FTC Antitrust Suit

FDA’s Case for Quality Targets Continuous Improvement — Not Just Compliance

  • Post author:PacConAdmin
  • Post published:July 3, 2023
  • Post category:Drug Industry Daily

The Case for Quality (CfQ) — an FDA initiative in which the agency works closely with the public-private partnership the Medical Device Innovation Consortium (MDIC) — has key programs coming…

Continue ReadingFDA’s Case for Quality Targets Continuous Improvement — Not Just Compliance

Expansion, Clarification Needed for Guidance on Incorporating COAs Into Endpoints

  • Post author:PacConAdmin
  • Post published:July 3, 2023
  • Post category:Drug Industry Daily

Feedback on the FDA’s draft guidance for incorporating clinical outcome assessments (COA) into endpoints has trickled in from a number of stakeholders, including BIO and the International Society for Cell…

Continue ReadingExpansion, Clarification Needed for Guidance on Incorporating COAs Into Endpoints

Legislative Update — Week of July 3, 2023

  • Post author:PacConAdmin
  • Post published:July 3, 2023
  • Post category:Drug Industry Daily

As the 118th Congress continues, FDAnews will track important pending legislation to keep you updated on regulations that could impact your business. Source: Drug Industry Daily

Continue ReadingLegislative Update — Week of July 3, 2023

Pre-Determined Change Plans Not Needed for AI/ML, Former Director at CDRH Says

  • Post author:PacConAdmin
  • Post published:June 30, 2023
  • Post category:Drug Industry Daily

While most comments on the FDA’s draft guidance on providing predetermined change plans for devices that include use of AI or machine learning (ML) offer improvements of one sort or…

Continue ReadingPre-Determined Change Plans Not Needed for AI/ML, Former Director at CDRH Says

Supply Chain at Risk in Every Industry FDA Regulates, Associate Commissioner Says

  • Post author:PacConAdmin
  • Post published:June 30, 2023
  • Post category:Drug Industry Daily

Deeply embedded supply chain challenges, such as “just in time” manufacturing methodology and sole sourcing to maximize profit, are key drivers of low inventories and offshoring, said Mark Abdoo, associate…

Continue ReadingSupply Chain at Risk in Every Industry FDA Regulates, Associate Commissioner Says

FDA Class I Recall for Certain Arrow Catheters that May Separate During Use

  • Post author:PacConAdmin
  • Post published:June 30, 2023
  • Post category:Drug Industry Daily

Certain recalled extended dwell catheters from Teleflex, and its subsidiary Arrow International, have a risk of separating while still in the blood vessel, resulting in the FDA deeming the recall…

Continue ReadingFDA Class I Recall for Certain Arrow Catheters that May Separate During Use

Using Risk-Based Thinking to Avoid Catastrophic Failures

  • Post author:PacConAdmin
  • Post published:June 30, 2023
  • Post category:Drug Industry Daily

Drugmakers should make use of risk-based thinking to help prevent “catastrophic failures,” said quality expert Amanda McPharland in a June 14 WCG FDAnews webinar. Source: Drug Industry Daily

Continue ReadingUsing Risk-Based Thinking to Avoid Catastrophic Failures

Regulatory Update — Week of June 26, 2023

  • Post author:PacConAdmin
  • Post published:June 30, 2023
  • Post category:Drug Industry Daily

Over the past week, the FDA issued final guidances on direct-to-consumer promotional labeling and advertisements and treatment for chronic rhinosinusitis with nasal polyps. Draft guidances were issued on psychedelic drugs,…

Continue ReadingRegulatory Update — Week of June 26, 2023
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.